PAM
JAZZ icon

Premier Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Premier Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-53,888
Closed -$9.57M – 182
2021
Q2 		$9.57M Buy
+53,888
New +$9.33M 1.41% 32

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Premier Asset Management's JAZZ Position: Q3 2021 in Review

Premier Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 53,888 shares — an estimated $9.57M sold.

Premier Asset Management first reported a position in JAZZ in Q2 2021 and held it in 1 quarter. The position peaked at $9.57M in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

  • Premier Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Premier Asset Management sold 53,888 Jazz Pharmaceuticals shares in Q3 2021, an estimated $9.57M.
  • Premier Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Premier Asset Management's Jazz Pharmaceuticals position peaked at $9.57M in Q2 2021.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Premier Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.